Advocacy groups recently used social media to sway the biopharma industry. And not only did the effort – which involved a high-profile influencer – alter a decade-long battle over access to tuberculosis products, but it may embolden other advocates to use social media to best companies at their own game.
The John Green Effect: Will Industry Be Influenced Again?
The Fault In Our Global Access To Medicines Practices
Drug and device makers regularly use media to sway consumers. But some advocacy groups recently turned the tables by using social media to sway industry.

More from Business Strategy
In Vivo looks at the top partnerships and investments in AI-driven companies in 2024. Collaborations and investments spanned multiple therapeutic areas, with a particular focus on small molecule discovery, protein degradation and neurological diseases.
The biotech industry faces a surge in litigation due to stricter regulations and patent disputes. This legal storm challenges companies and investors, but there are proactive strategies for mitigating risk in this dynamic landscape.
In September last year, J&J lost a court case surrounding its 2019 purchase of Auris health, and was ordered to pay over $1bn in damages. Reactions to the potentially precedent-setting news were harsh and quick. In Vivo spoke to legal, M&A and BD experts from across the medtech industry to learn more about the true impacts.
Risk management and the need for back-up systems are fast emerging as themes that users of artificial intelligence tools in health care settings must face up to. Now more comfortable with the technology’s capabilities, health care stakeholders appreciate that there can be two sides to the AI coin.
More from In Vivo
For In Vivo's 17th annual Deals of the Year contest, we selected 12 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.
In the latest episode of the In Vivo podcast, Citeline’s expert panel of reporters and analysts unpack the biggest deals, trends and innovations following the J.P. Morgan Healthcare Conference.
All the elements for a big M&A year are in place, but political uncertainty and interest rates could push more deals into the second half of the year, according to business development experts at BIO CEO & Investor.